ArticleBMC microbiology2026
The impact of faster antimicrobial susceptibility testing report and dual antimicrobial susceptibility testing cards on the antibiotic therapy and economics of hospitalized bloodstream infection patients.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOveruse of carbapenems and other broad-spectrum antibiotics increases both costs and the risk of antimicrobial resistance (AMR). This study assessed whether optimizing antimicrobial susceptibility testing (AST) reports could improve clinical and economic outcomes for hospitalized patients with bloodstream infections (BSIs).
methodsFrom June 2022 to May 2023, a series of microbiology laboratory interventions were implemented at the Affiliated Hospital of North Sichuan Medical College, including the use of BacT/Alert Virtuo system (bioMérieux, France) for rapid loading, VITEK MS (bioMérieux, France) for rapid microbiology identification (ID), 24-hour laboratory service, and dual AST cards (N335 + XN04) replacing the single card (GN13). Previous simultaneously reported ID and AST results were successfully replaced by a separate reporting process. Data from BSI patients before (June 2021-May 2022) and after (June 2023-May 2024) interventions were retrospectively analyzed for ID and AST reporting time, antibiotic use, length of stay (LOS), and costs.
resultsA total of 256 BSI patients were analyzed (125 pre-intervention; 131 post-intervention). The post-intervention group had significantly shorter times to ID (median 41.26 vs. 74.35 h) and AST reports (56.02 vs. 74.35 h), with earlier opportunities for targeted antibiotic adjustments. Antibiotic modifications occurred ~ 36 h sooner within the first 72 h. Among all agents, carbapenems underwent the most MIC-based changes (20 additions and 10 discontinuations), reflecting improved carbapenem stewardship driven by expanded AST coverage. Post-intervention patients also showed shorter LOS, reduced antibiotic and testing costs, and a potential improvement in survival, especially in ICU cases.
conclusionsOptimized microbiology workflows, including dual AST cards and faster AST report, significantly accelerated reporting and facilitated timely, precise antimicrobial therapy, particularly carbapenem stewardship, while reducing clinical and economic burdens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.